Skip to main content



Moberg Pharma – a different kind of pharma company



A business model with faster time to market and lower development risk compared with conventional drug development



Each year, we evaluate in excess of 100 new business opportunities to identify future bestsellers



We build strong OTC brands



We sell Kerasal Nail through 30,000 retail outlets in the U.S

Moberg Pharma is a rapidly growing Swedish pharmaceutical company that commercializes proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases but is now widening its scope to include additional areas. We market OTC brands in the U.S. and sell through distributors in more than 40 countries.

Stockvalue 2013-05-20 14:00
32,90 kr
+2,5 %
Interview with CEO Peter Wolpert
Our global markets
  • All pressreleases
  • Regulatory


Get our latest press releases and reports


Latest report

2018-04-10 Moberg Pharma Annual Report 2017


Next calendar event: 2018-05-08 Interim report for January - March 2018

Increased sales

Mycological cure rate after MOB-015 treatment